SCHEMBL3068285

SCHEMBL3068285

O=C(O)c1cnn(-c2ccccc2)c1N1CCCC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.64
KEAP1 Q14145 1/20 0.55
NFE2L2 Q16236 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.52
MAPT P10636 3/20 0.52
NR4A3 Q92570 1/20 0.52
POLB P06746 1/20 0.52
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
HPGD P15428 2/20 0.48
MAPK1 P28482 3/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RIPK2 O43353 1/20 0.48
ALDH1A1 P00352 3/20 0.47
HTT P42858 1/20 0.46
MAPK14 Q16539 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3063443 0.98 L3MBTL1 (0.62) L3MBTL1KEAP1NFE2L2SMN1; SMN2MAPT
SCHEMBL3081183 0.87 L3MBTL1 (0.59) L3MBTL1KEAP1NFE2L2SMN1; SMN2MAPT
SCHEMBL3057279 0.86 L3MBTL1 (0.58) L3MBTL1KEAP1NFE2L2SMN1; SMN2MAPT
SCHEMBL3067178 0.84 L3MBTL1 (0.53) L3MBTL1KEAP1NFE2L2SMN1; SMN2MAPT
SCHEMBL3070448 0.83 MAPT (0.54) L3MBTL1KEAP1NFE2L2SMN1; SMN2MAPT
SCHEMBL27783371 0.81 L3MBTL1 (0.50) L3MBTL1KEAP1NFE2L2SMN1; SMN2MAPT
SCHEMBL3075062 0.81 L3MBTL1 (0.56) L3MBTL1KEAP1NFE2L2SMN1; SMN2MAPT
SCHEMBL4770722 0.78 L3MBTL1 (1.00) L3MBTL1KEAP1NFE2L2SMN1; SMN2MAPT
SCHEMBL27783409 0.78 L3MBTL1 (0.56) L3MBTL1KEAP1NFE2L2SMN1; SMN2MAPT
SCHEMBL3067306 0.78 HSD11B1 (0.57) SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790711-B2 Inhibitors of 11β-Hydroxysteroid Dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-09-07 US disclosed
US-20090023709-A1 Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase GILLESPIE PAUL 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023709-A1 Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase HSD17B1, HSD17B2, HSD11B1 L3MBTL1 3753/4885KEAP1 1004/4885NFE2L2 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.